Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites

References

• BENSOUSSAN, C., DELAFORGE, M. and MANSUY, D., 1995, Particular ability of cytochromes P450 3A to form inhibitory P450—iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology, 49, 591–602.
   PubMed Web of Science ®Google Scholar
• BORGNA, J. L. and ROCHEFORT, H., 1981, Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. Journal of Biological Chemistry, 256, 859–868.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H. G., RIEGELMAN, S. and ELASHO, R. M., 1974, Statistical estimations in pharma- cokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 2, 123–148.
   PubMedGoogle Scholar
• BUCKLEY, M. M. and Gow, K. L., 1989, Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs, 37, 451–490.
   PubMed Web of Science ®Google Scholar
• CHIBA, M., NISHIME, J. A. and LIN, J. H., 1995, Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. Journal of Pharmacology and Experimental Therapeutics, 275, 1527–1534.
   PubMed Web of Science ®Google Scholar
• COMOGLIO, A., GIBBS, A. H., WHITE, I. N. H., GANT, T., MARTIN, E. A., SMITH, L. L., GAMALERO, S. R. and DEMATTEIS, F., 1996, Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the Rhesus monkey: does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer? Carcinogenesis, 17, 1687–1693.
   Google Scholar
• CRESPI, C. L., PENMAN, B. W., STEIMEL, D. T., SMITH, T., YANG, C. S. and SUTTER, T. R., 1997, Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis, 12, 83–89.
   PubMed Web of Science ®Google Scholar
• CREWE, H. K., Ews, S. W., LENNARD, M. S. and TUCKER, G. T., 1997, Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochemical Pharmacology, 53, 171–178.
   PubMed Web of Science ®Google Scholar
• DEHAL, S. and KUPFER, D., 1997, CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Research, 57, 3402–3406.
   PubMed Web of Science ®Google Scholar
• DEHAL, S. and KUPFER, D., 1999, Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins. Drug Metabolism and Disposition, 27, 681–688.
   PubMed Web of Science ®Google Scholar
• DIVER, J. M. J., JACKSON, I. M. and FITZGERALD, J. D., 1986, Tamoxifen and nonmalignant indications. Lancet, i, 733.
   Google Scholar
• DOWSETT, M., PSTER, C., JOHNSTON, S. R. D., MILES, D. W., HOUSTON, S. J., VERBEEK, J. A., GUNDACKER, H., Siou, A. and SMITH, I. E., 1999, Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clinical Cancer Research, 5, 2338–2343.
   Google Scholar
• EVANS, W. E. and RELLING, M. V., 1989, Clinical pharmacokinetics—pharmacodynamics of anticancer drugs. Clinical Pharmacokinetics, 16, 327–336.
   PubMed Web of Science ®Google Scholar
• FISHER, B., COSTANTINO, J. P., WICKERHAM, D. L., REDMOND, C. K., KAVANAH, M., CRONIN, W. M., VOGEL, V., ROBIDOUX, A., DIMITROV, N., ATKINS, J., DALY, M., WIEAND, S., TAN-CHIU, E., FORD, L. and WOLMARK, N., 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowl Project-1 Study. Journal of the National Cancer Institute, 90, 1371–1388.
   Google Scholar
• FRANKLIN, M. R., 1977, Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacological Therapeutics, 2, 227–245.
   Web of Science ®Google Scholar
• FURR, B. J. A AND JORDAN, V. C., 1984, The pharmacology and clinical uses of tamoxifen. Pharmacological Therapeutics, 25, 127–205.
   PubMed Web of Science ®Google Scholar
• GUNS, M. A., THUMMEL, K. E., SHEN, D. and KUNZE, K. L., 1999, Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metabolism and Disposition, 27, 180–187.
   PubMed Web of Science ®Google Scholar
• GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643–1653.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1986, Covalent binding to apoprotein is a major fate of heme in a variety of reactions in which cytochrome P-450 is destroyed. Biochemistry and Biophysical Research Communications, 138, 193–198.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOL, T. and WAXMAN, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051–5060.
   PubMed Web of Science ®Google Scholar
• JACOLOT, F., SIMON, I., DREANO, Y., BEAUNE, P., RICHE, C. and BERThou, F., 1991, Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochemical Pharmacology, 41,1911–1919.
   PubMed Web of Science ®Google Scholar
• JONES, D. R., GORSKI, J. C., HAMMAN, M. A., MAYHEW, B. S., RIDER, S. and HALL, S. D., 1999, Diltiazem inhibition of CYP3A activity is due to metabolite intermediate complex formation. Journal of Pharmacology and Experimental Therapeutics, 290, 1116–1125.
   PubMed Web of Science ®Google Scholar
• KENWORTHY, K. E., BLOOMER, J. C., CLARKE, S. E. and HOUSTON, J. B., 1999, CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British journal of Clinical Pharmacology, 48, 716–727.
   PubMed Web of Science ®Google Scholar
• KING, C. M., 1995, Tamoxifen and the induction of cancer. Carcinogenesis, 16, 1449–1454.
   PubMed Web of Science ®Google Scholar
• KIVISTO, K. T., KROEMER, H. K. and EICHELBAU M., 1995, The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. British Journal of Clinical Pharmacology, 40, 523–530.
   PubMed Web of Science ®Google Scholar
• KOLARS, J. C., SCHMIEDLIN-REN, P., SCHUETZ, J. D., FANG, C. and WATKINS, P. B., 1992, Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. journal of Clinical Investigation, 90, 1871–1878.
   Google Scholar
• KOUDRIAKOVA, T., IATSIMIRSKAIA, E., UTKIN, I., GANGL, E., VOUROS, P., ELENA, S., ORZA, D., MARINNA, J. and GERBER, N., 1998, Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/ 3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabolism and Disposition, 26, 552–561.
   PubMed Web of Science ®Google Scholar
• KUEHL, P., ZHANG, J., LIN, Y., LAMBA, J., ASSEM, M., SCHUETZ, J., WATKINS, P. B. DALY, A., WRIGHTON, S. A., HALL S. D., MAUREL, P., RELLING, M., BRIMER, C., YASUDA, K., VENKATARAMANAN, R., STROM, S., THUMMEL, K., Boutisiti, M. S. and SCHUETZ, E., 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383–391.
   Google Scholar
• LIM, C. K., YUAN, Z.H., LAMB, J. H., WHITE, I. N. H., DE MATTEIS, F. and SMITH, L. L., 1994, A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis (Oxf), 15, 589–593.
   Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MANI, C., GELBOIN, H. V., PARK, S. S., PEARCE, R., PARKINSON, A. and KUPFER, D. 1993a, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen: I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metabolism and Disposition, 21, 645–656.
   PubMed Web of Science ®Google Scholar
• MANI, C., HODGSON, E. and KUPFER, D., 1993b, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen: II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metabolism and Disposition, 21, 657–661.
   PubMed Web of Science ®Google Scholar
• MAYHEW, B. S., JONES, D. R. and HALL, S. D., 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition, 28, 1031–1037.
   PubMed Web of Science ®Google Scholar
• MILLWARD, M. J., CANTWELL, B. M. J., LIEN, E. A., CARMICHAEL, J. and HARRIS, A. L., 1992, Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. European Journal of Cancer, 28A, 805–810.
   Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. journal of Biological Chemistry, 239, 2379–2385.
   PubMed Web of Science ®Google Scholar
• PEYRADE, F., FRENAY, M., ETIENNE, M.-C, Ruch, F., Guillemare, C., Francois, E., Namer, M., Ferrero, J.-M. and MILANO, G., 1996, Age-related difference in tamoxifen disposition. Clinical Pharmacology and Therapeutics, 59, 401–410.
   Google Scholar
• POON, G. K., CHUI, Y. C., MCCAGUE, R., LONNING, P. E., FENG, R., ROWLANDS, M. G. and JARMAN, M., 1993, Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism and Disposition, 21, 1119–1124.
   PubMed Web of Science ®Google Scholar
• REUNITZ, P. C., BAGLEY, J. R. and PAPE, C. W., 1984, Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metabolism and Disposition, 12, 478–483.
   PubMed Web of Science ®Google Scholar
• SCHAEFER, W. H., Hmuus, T. M. and GUENGERICH, F. P., 1985, Characterization of the enzymatic and nonenzymatic peroxidative degradation of iron porphyrins and cytochrome P450 heme. Biochemistry, 24, 3254–3263.
   PubMed Web of Science ®Google Scholar
• SEGEL, I. H., 1975, Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (New York: Wiley).
   Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGRICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SILVERMAN, R. B., 1988, Mechanism-based Enzyme Inactivation: Chemistry and Enzymology (Boca Raton: CRC Press), vol. 1, pp. 3–30.
   Google Scholar
• SRIDOR, C., KENT, U. M. and HOLLENSERG, P. F., 1999, Effect of tamoxifen on the enzymatic activity of human cytochrome P450 2B6. /SSX Proceedings, 15, 99.
   Google Scholar
• SUTTON, D., BUTLER, A. M., NADLIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294–300.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., WRIGHTON, S. A., SCHUETZ, E. G., MoLowa, D. T. and GUZELIAN, P. S., 1987, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. Journal of Clinical Investigation, 80, 1029–1036.
   PubMed Web of Science ®Google Scholar
• WIRZ, B., VALLES, B., PARKINSON, A., MADAN, A., PROBST, A., ZIMMERLIN, A. and GUT, J., 1996, CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (FEMARA1). ISSX Proceedings, 10, 359.
   Google Scholar